肾移植术后肾功能延迟恢复原因及术后血液净化的干预作用

目的：分析肾移植术后常见并发症肾功能延迟恢复的诱因，并观察术后血液净化干预所发挥的临床效应。方法：选择1996—12/2006—12在解放军第三军医大学大坪医院野战外科研究所泌尿外科明确诊断为肾移植术后肾功能延迟恢复的患者193例，其中接受尸肾移植192例，活体肾移植1例，均知情同意。根据患者的临床资料，分析术后肾功能延迟恢复的主要原因。除5例因术前安置腹膜透析管继续采用腹膜透析外，其余均选择血液透析治疗，其中35例穿插接受过连续性肾脏替代治疗或血液透析滤过，8例血浆置换2-5次。终止透析的标准为每日尿量〉1500mL，血肌酐〈300μmol／L。分析术后肾功能延迟恢复的原因，观察接受透析治疗后肾功能延迟恢复患者的临床疗效。结果：193例患者全部进入结果分析。①术后肾功能延迟恢复的病因：急性肾小管坏死89例（46．1％），术后早期低血压42例（21．8％），排斥反应37例（19．2％），动静脉吻合口狭窄9例（4-7％），尿路梗阻8例（4．1％），动脉过长扭曲5例（2．6％），环孢素A肾毒性2例（1．0％），髂内动脉粥样硬化斑块阻塞1例（0．5％）。（④术后肾功能转归：移植肾功能恢复正常者145例（75．1％）；术后3个月血肌酐135-300μmol／L29例（15．3％）；〉300μmol/L15例（7．8％）；因超急性排斥反应切除移植肾2例（1％），肺部重症感染死亡2例（1％）。③术后接受血液透析次数：术后接受血液透析189例，透析1—5次移植肾功能恢复正常20例（13．8％）；6-10次41例（28．3％）；11-20次82例（56．6％）；21-25次2例（1．4％）；〉25次44例，仅1例恢复正常（0．7％），其余43例患者带肾存活。结论：急性肾小管坏死、术后早期低血压和排斥反应是引起肾移植术后肾功能延迟恢复的主要原因。在肾功能延迟恢复患者确定以血液净化为主的方案后，绝大多数移植肾功能可以恢复。     

慢性移植肾失功356例危险因素分析

目的:慢性移植肾失功是导致后期移植肾丧失的重要原因之一,文章拟探讨慢性移植肾失功的相关因素及防治措施。方法:①选择1993-12/2006-12于解放军第三军医大学大坪医院行肾移植术后发生慢性移植肾失功患者356例,回顾性分析其临床资料。②调整免疫抑制剂方案,停服硫唑嘌呤、环孢素A或减少环孢素A30%￣50%剂量,改用他克莫司0.5￣1mg/(kg·d)、霉酚酸酯1￣2g/d、西罗莫司1￣2mL/d等药;控制血糖、血脂、血压,抗凝及补充鱼肝油丸;服用雷公藤、百令胶囊或尿毒清等中药,给予低蛋白、低磷及高维生素、氨基酸饮食;必要时手术切除移植肾。③分析肾移植术后发生慢性移植肾失功的危险因素并观察其治疗结果。结果:①慢性移植肾失功的危险因素:急性排斥反应254例(71.35%),巨细胞病毒感染65例(18.26%),移植肾肾小球肾炎21例(5.9%),药物中毒(环孢素A/他克莫司)9例(2.53%),高血压/高血脂/高血糖5例(1.41%),肾单位减少(高龄供肾/性别差异)2例(0.56%)。②治疗结果:切除移植肾194例(54.49%),带肾存活、恢复血液透析87例(24.44%),经治疗血肌酐维持在200￣300μmol/L63例(17.70%),死亡12例(3.37%)。结论:急性排斥反应是引起肾移植术后慢性移植肾失功的主要因素。提高供肾质量,严格组织配型,减少移植肾功能延迟恢复的发生,制定个体化免疫方案,定期监测药物浓度及肝肾功能,预防巨细胞病毒感染,可减少慢性移植肾失功的发生。     

Idiopathic spinal epidural lipomatosis without obesity: a case with relapsing and remitting course

STUDY DESIGN: Case report of a rare form of idiopathic spinal epidural lipomatosis (SEL) manifesting with relapsing and remitting course. OBJECTIVE: To describe this very rare clinical and pathological condition and the results of surgical intervention. SETTING: A department of neurosurgery in Morocco. METHODS: A 24-year-old man presented with a 2-year history of mid-thoracic back pain and progressive neurogenic claudication with two episodes of remitting and relapsing course. Spinal magnetic resonance imaging revealed a fatty epidural mass extending from T4 to T9. Posterior decompression was performed, and he was followed for 3 years after the operation. RESULTS: Pathological examination of the surgical specimen revealed nodules of mature fat cells without neoplasm. The patient's symptoms completely resolved after surgical decompression. CONCLUSION: Fluctuating clinical course has not been reported previously in SEL. Such pathology should be considered in the differential diagnosis of demyelinating diseases.     

Molecular testing of human papillomavirus in cervical specimens

OBJECTIVE: To improve the diagnosis of cervical neoplasia by early detection of human papillomavirus (HPV) in uterine cervix, by adding molecular testing of HPV using hybrid capture 2 (HC2) and polymerase chain reaction (PCR) tests to Papanicolaou (Pap) test. METHODS: One hundred women were enrolled in this study. The mean age (mean +/- SD) was 41.97 +/- 8.76 years and the range was 27-65 years. All women had undergone cervical cytological screening with cervical cytology, HPV DNA testing by HC2 and PCR, during the period from January - December 2006, at King Abdul-Aziz University Hospital (KAAUH) and King Fahd Research Centre, Jeddah, Saudi Arabia. RESULTS: The results we obtained by HC2 for detection of HPV were 5 (5%) high-risk HPV, one low-risk HPV (1%) and 94 (94%) negative cases. The PCR detected only 4 (4%) cases. Using the HC2 test as a reference, the sensitivity, specificity, positive predictive, negative predictive values and accuracy of baseline Pap were 50, 85, 17.7, 96.4, and 83%; of final Pap smear were 100, 96.8, 66.7, 100, 97%, and for PCR were 66.7, 100, 100, 97.9, and 98%. The Pap test was repeated within a year for patients with abnormal Pap or negative Pap test with positive HPV DNA. CONCLUSION: Combined screening by cytology and HPV testing using both HC2 and PCR sensitively detects women with existing disease. The absence of HPV DNA provides reassurance that patients are unlikely to develop cancer for several years. We suggest using Pap with HC2 and PCR in screening programs to ensure that women with the double negative result at baseline might safely be screened at longer intervals.     

Biological immunomodulators improve the healing rate in surgically treated perianal Crohn’s fistulas

Aim The role of biological therapy in perianal fistulas associated with Crohn’s disease (CD) is uncertain as available data are confused and conflicting. In order to provide some clarity to the issue we have examined a large cohort of patients with perianal fistulas and CD and stratified them according to use of biological agents. Method Patients with perianal Crohn’s fistulas treated between June 1999 and June 2009 were stratified according to use of biological agents and outcome was examined. Healing was defined as absence of fistula or drainage. Prior to surgery perianal sepsis was eradicated with drains or setons. Endpoints were defined as either complete healing, improvement (minimal symptoms and drainage) or unhealed, as noted at subsequent outpatient follow‐up. Variables assessed were age, body mass index, smoking, perineal involvement with Crohn’s granuloma and type of procedure. Fisher’s exact test and χ² test were used for analysis. Results Two hundred and eighteen patients had anal fistulas and CD. Mean follow‐up was 3.2 ± 3 years with mean age 38.8 ± 12.2 years and body mass index of 25.3 ± 6. One hundred and seventeen patients (53.7%) underwent surgery alone (Group A) and 101 patients (46.3%) underwent surgery and biological immunomodulator treatments (Group B). Demographic data and CD history were similar between groups. Surgeries included seton drainge (n = 90), fistulotomy (n = 22), rectal advancement flap (n = 39), fistulotomy plus seton (n = 47) and others (n = 20). Overall improvement in Group A was in 42 patients (35.9%) vs 72 patients (71.3%) in Group B (P = 0.001). There was no significant difference in other studied variables between both groups. Conclusions There is a definite role for biological therapy as an adjuvant to surgery in patients with perianal fistulas and CD.